Centre National De La Recherche Scientifique

Francois Dautry

Anne Chauchereau

Florence Cabon-Georget

Annick Harel-Bellan

Slimane Ait-Si-Ali

Luis Martinez

A double-strand oligonucleotide including two complementary oligonucleotide sequences forming a hybrid, each including at one of their 3' or 5&#x2032; ends, one to five unpaired nucleotides forming single-strand ends extending beyond the hybrid, one of the oligonucleotide sequences being substantially complementary to a target sequence belonging to a DNA or RNA molecule to be specifically repressed, the target sequence belonging to a DNA or RNA molecule of a gene coding an angiogenic factor.

SiRNA-based cancer treatment

A method of treating a disease resulting from the expression of a harmful gene is described. The method includes the step of administering a therapeutically effective amount of a pharmaceutical composition having at least one double stranded oligonucleotide including two complementary oligonucleotide sequences forming a hybrid. Each oligonucleotide sequence comprises at one of their 3' or 5&#x2032; ends one to five unpaired nucleotides forming single-strand ends extending beyond the hybrid. One of the oligonucleotide sequences is substantially complementary to a target sequence belonging to a DNA or messenger RNA molecule of a gene coding a mutated or nonmutated androgen receptor.

Growing community of inventors

Paris, France

Francois Dautry